Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,472
Recruiting: 1,283
Ph III recruiting: 130
Growth YoY: +4.1%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,642)

clinicaltrialsPublishedShowing 101–150 of 461 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06528301	A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies	recruiting	Phase 1	106	Umoja BiopharmaINDUSTRY	2	Aug 17, 2026	clinicaltrials
NCT06927466	A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.	recruiting	Phase 1	33	Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.INDUSTRY	1